MARKET

PYXS

PYXS

Pyxis Oncology, Inc.
NASDAQ
1.460
+0.190
+14.96%
Closed 19:49 03/31 EDT
OPEN
1.330
PREV CLOSE
1.270
HIGH
1.460
LOW
1.310
VOLUME
357.08K
TURNOVER
0
52 WEEK HIGH
5.55
52 WEEK LOW
0.8332
MARKET CAP
91.73M
P/E (TTM)
-1.1395
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PYXS last week (0323-0327)?
Weekly Report · 2d ago
Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst
TipRanks · 3d ago
Pyxis Oncology; Director Rachel Humphrey disposes of common shares worth $16,682
Reuters · 6d ago
Pyxis Oncology Price Target Cut to $8.00/Share From $9.00 by Stifel
Dow Jones · 03/24 13:31
Pyxis Oncology Is Maintained at Buy by Stifel
Dow Jones · 03/24 13:31
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Lifecore Biomedical (LFCR), Pyxis Oncology (PYXS) and Bausch + Lomb Corporation (BLCO)
TipRanks · 03/24 12:40
Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/24 11:15
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
Benzinga · 03/24 11:06
More
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Webull offers Pyxis Oncology Inc stock information, including NASDAQ: PYXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PYXS stock methods without spending real money on the virtual paper trading platform.